PARP (poly ADP-ribose polymerase) inhibitors are currently used to treat inoperable or recurrent breast cancer that is germline BRCA pathogenic/likely pathogenic mutation-positive and HER2-negative with a history of prior cancer chemotherapy [45]. This evidence concerns the gene ERBB2 and cancer.